SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 11/25/20 NTN Buzztime Inc. S-4/A 207:22M M2 Compliance LLC/FA |
Document/Exhibit Description Pages Size 1: S-4/A Pre-Effective Amendment to Registration Statement HTML 4.43M - Securities for a Merger 2: EX-5.1 Opinion of Counsel re: Legality HTML 58K 3: EX-10.16(A) Material Contract HTML 72K 4: EX-10.16(B) Material Contract HTML 74K 5: EX-10.17(A) Material Contract HTML 72K 6: EX-10.17(B) Material Contract HTML 58K 7: EX-10.17(C) Material Contract HTML 74K 8: EX-10.17(D) Material Contract HTML 66K 9: EX-10.18 Material Contract HTML 74K 10: EX-10.19(A) Material Contract HTML 235K 11: EX-10.19(B) Material Contract HTML 61K 12: EX-10.19(C) Material Contract HTML 72K 13: EX-10.20 Material Contract HTML 126K 14: EX-10.21 Material Contract HTML 68K 15: EX-10.22 Material Contract HTML 71K 16: EX-10.23(A) Material Contract HTML 284K 17: EX-10.23(B) Material Contract HTML 63K 18: EX-10.23(C) Material Contract HTML 66K 19: EX-10.23(D) Material Contract HTML 101K 20: EX-10.24(A) Material Contract HTML 219K 21: EX-10.24(B) Material Contract HTML 77K 22: EX-10.24(C) Material Contract HTML 66K 23: EX-23.4 Consent of Expert or Counsel HTML 54K 24: EX-23.5 Consent of Expert or Counsel HTML 54K 25: EX-99.1 Miscellaneous Exhibit HTML 53K 27: EX-99.10 Miscellaneous Exhibit HTML 54K 28: EX-99.11 Miscellaneous Exhibit HTML 54K 29: EX-99.12 Miscellaneous Exhibit HTML 54K 30: EX-99.13 Miscellaneous Exhibit HTML 54K 26: EX-99.9 Miscellaneous Exhibit HTML 54K 37: R1 Document and Entity Information HTML 68K 38: R2 Condensed Consolidated Balance Sheets HTML 171K 39: R3 Condensed Consolidated Balance Sheets HTML 83K (Parenthetical) 40: R4 Condensed Consolidated Statements of Operations HTML 134K and Comprehensive Loss (Unaudited) 41: R5 Condensed Consolidated Statements of Operations HTML 56K and Comprehensive Loss (Unaudited) (Parenthetical) 42: R6 Condensed Consolidated Statements of Shareholders' HTML 122K Equity (Unaudited) 43: R7 Condensed Consolidated Statements of Cash Flows HTML 195K (Unaudited) 44: R8 Condensed Balance Sheets (Brooklyn HTML 144K ImmunoTherapeutics, LLC) 45: R9 Condensed Statements of Operations (Unaudited) HTML 103K (Brooklyn ImmunoTherapeutics, LLC) 46: R10 Condensed Statements of Changes in Members' Equity HTML 149K (Brooklyn ImmunoTherapeutics, LLC) 47: R11 Condensed Statements of Cash Flows (Brooklyn HTML 265K ImmunoTherapeutics, LLC) 48: R12 Basis of Presentation HTML 62K 49: R13 Organization of Company HTML 61K 50: R14 Merger Agreement and Asset Purchase Agreement HTML 60K 51: R15 Covid-19-Update HTML 59K 52: R16 Going Concern Uncertainty HTML 66K 53: R17 Summary of Significant Accounting Policies And HTML 131K Estimates 54: R18 Restricted Cash HTML 59K 55: R19 Fixed Assets, Net HTML 65K 56: R20 Fair Value of Financial Instruments HTML 62K 57: R21 Accrued Compensation HTML 61K 58: R22 Concentrations of Risk HTML 60K 59: R23 Revenue Recognition HTML 112K 60: R24 Basic and Diluted Earnings Per Common Share HTML 59K 61: R25 Shareholders' Equity HTML 116K 62: R26 Income Taxes HTML 87K 63: R27 Debt HTML 66K 64: R28 Long-term Debt HTML 59K 65: R29 Leases HTML 110K 66: R30 Commitments and Contingencies HTML 58K 67: R31 Disposition of Site Equipment to Be Installed and HTML 61K Fixed Assets 68: R32 Software Development Costs HTML 60K 69: R33 Goodwill HTML 66K 70: R34 Accumulated Other Comprehensive Income HTML 59K 71: R35 Recent Accounting Pronouncements HTML 65K 72: R36 Retirement Savings Plan HTML 57K 73: R37 Subsequent Events HTML 65K 74: R38 Organization and Description of Business HTML 65K Operations (Brooklyn ImmunoTherapeutics, LLC) 75: R39 Description of Business (Brooklyn HTML 57K ImmunoTherapeutics, LLC) (10-K) 76: R40 Going Concern (Brooklyn ImmunoTherapeutics, LLC) HTML 72K 77: R41 Basis of Presentation and Summary of Significant HTML 72K Accounting Policies (Brooklyn ImmunoTherapeutics, LLC) 78: R42 Summary of Significant Accounting Policies HTML 150K (Brooklyn ImmunoTherapeutics, LLC) (10-K) 79: R43 Merger With NTN Buzztime, Inc (Brooklyn HTML 59K ImmunoTherapeutics, LLC) 80: R44 Fair Value of Financial Instruments (Brooklyn HTML 74K ImmunoTherapeutics, LLC) 81: R45 Business Combination (Brooklyn ImmunoTherapeutics, HTML 61K LLC) (10-K) 82: R46 Property and Equipment (Brooklyn HTML 76K ImmunoTherapeutics, LLC) 83: R47 Goodwill and in Process Research and Development HTML 56K (Brooklyn ImmunoTherapeutics, LLC) (10-K) 84: R48 Security Deposits and Other Assets (Brooklyn HTML 58K ImmunoTherapeutics, LLC) 85: R49 Accrued Expenses (Brooklyn ImmunoTherapeutics, HTML 65K LLC) 86: R50 Investor Deposits (Brooklyn ImmunoTherapeutics, HTML 55K LLC) (10-K) 87: R51 Loans Payable (Brooklyn ImmunoTherapeutics, LLC) HTML 68K 88: R52 Loans Payable and Loans Payable to Related Parties HTML 59K (Brooklyn ImmunoTherapeutics, LLC) (10-K) 89: R53 Commitments and Contingencies (Brooklyn HTML 82K ImmunoTherapeutics, LLC) 90: R54 Stock-Based Compensation (Brooklyn HTML 62K ImmunoTherapeutics, LLC) 91: R55 Members' Equity (Brooklyn ImmunoTherapeutics, LLC) HTML 57K 92: R56 Stockholders' Deficiency and Members' Equity HTML 75K (Brooklyn ImmunoTherapeutics, LLC) (10-K) 93: R57 Income Tax (Brooklyn ImmunoTherapeutics, LLC) HTML 101K (10-K) 94: R58 Subsequent Events (Brooklyn ImmunoTherapeutics, HTML 72K LLC) 95: R59 Summary of Significant Accounting Policies And HTML 180K Estimates (Policies) 96: R60 Basis of Presentation and Summary of Significant HTML 96K Accounting Policies (Policies) (Brooklyn ImmunoTherapeutics, LLC) 97: R61 Summary of Significant Accounting Policies HTML 129K (Policies) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 98: R62 Summary of Significant Accounting Policies And HTML 118K Estimates (Tables) 99: R63 Fixed Assets, Net (Tables) HTML 66K 100: R64 Accrued Compensation (Tables) HTML 59K 101: R65 Revenue Recognition (Tables) HTML 118K 102: R66 Shareholders' Equity (Tables) HTML 100K 103: R67 Income Taxes (Tables) HTML 84K 104: R68 Leases (Tables) HTML 95K 105: R69 Goodwill (Tables) HTML 63K 106: R70 Business Combination (Tables) (Brooklyn HTML 60K ImmunoTherapeutics, LLC) (10-K) 107: R71 Fair Value of Financial Instruments (Tables) HTML 63K (Brooklyn ImmunoTherapeutics, LLC) 108: R72 Property and Equipment (Tables) (Brooklyn HTML 70K ImmunoTherapeutics, LLC) 109: R73 Accrued Expenses (Tables) (Brooklyn HTML 64K ImmunoTherapeutics, LLC) 110: R74 Commitments and Contingencies (Tables) (Brooklyn HTML 59K ImmunoTherapeutics, LLC) (10-K) 111: R75 Stockholders' Deficiency and Members' Equity HTML 83K (Tables) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 112: R76 Income Tax (Tables) (Brooklyn ImmunoTherapeutics, HTML 89K LLC) (10-K) 113: R77 Basis of Presentation (Details Narrative) HTML 55K 114: R78 Organization of Company (Details Narrative) (10-K) HTML 61K 115: R79 Merger Agreement and Asset Purchase Agreement HTML 74K (Details Narrative) 116: R80 Covid-19-Update (Details Narrative) HTML 60K 117: R81 Going Concern Uncertainty (Details Narrative) HTML 97K 118: R82 Going Concern Uncertainty (Details Narrative) HTML 78K (10-K) 119: R83 Summary of Significant Accounting Policies and HTML 199K Estimates (Details Narrative) (10-K) 120: R84 Summary of Significant Accounting Policies and HTML 78K Estimates - Schedule of Disaggregation of Revenues (Details) (10-K) 121: R85 Summary of Significant Accounting Policies and HTML 61K Estimates - Schedule of Revenues Geographic Breakdown (Details) (10-K) 122: R86 Summary of Significant Accounting Policies and HTML 65K Estimates - Schedule of Contract Liabilities (Details) (10-K) 123: R87 Summary of Significant Accounting Policies and HTML 63K Estimates - Schedule of Unamortized Installation Cost and Sales Commissions (Details) (10-K) 124: R88 Restricted Cash (Details Narrative) HTML 72K 125: R89 Restricted Cash (Details Narrative) (10-K) HTML 75K 126: R90 Fixed Assets, Net (Details Narrative) (10-K) HTML 56K 127: R91 Fixed Assets, Net - Schedule of Property and HTML 70K Equipment (Details) (10-K) 128: R92 Fixed Assets, Net - Schedule of Asset Geographic HTML 59K Breakdown (Details) (10-K) 129: R93 Accrued Compensation - Schedule of Accrued HTML 66K Compensation (Details) (10-K) 130: R94 Concentrations of Risk (Details Narrative) (10-K) HTML 75K 131: R95 Revenue Recognition - (Details Narrative) HTML 62K 132: R96 Revenue Recognition - Schedule of Disaggregates HTML 78K Material Revenue (Details) 133: R97 Revenue Recognition - Schedule of Revenues HTML 62K Geographic Breakdown (Details) 134: R98 Revenue Recognition - Schedule of Contract HTML 66K Liabilities (Details) 135: R99 Revenue Recognition - Schedule of Unamortized HTML 64K Installation Cost and Sales Commissions (Details) 136: R100 Basic and Diluted Earnings Per Common Share HTML 57K (Details Narrative) 137: R101 Basic and Diluted Earnings Per Common Share HTML 57K (Details Narrative) (10-K) 138: R102 Shareholders' Equity (Details Narrative) HTML 102K 139: R103 Shareholders' Equity (Details Narrative) (10-K) HTML 171K 140: R104 Shareholders' Equity - Schedule of Weighted HTML 64K Average Assumptions (Details) 141: R105 Shareholders' Equity - Schedule of Weighted HTML 64K Average Assumptions (Details) (10-K) 142: R106 Shareholders' Equity - Schedule of Restricted HTML 58K Stock and Common Stock Unit Vested (Details) 143: R107 Shareholders' Equity - Summary of Stock Option HTML 104K Activity (Details) (10-K) 144: R108 Shareholders' Equity - Summary of Restricted Stock HTML 76K Unit Activity (Details) (10-K) 145: R109 Shareholders' Equity - Summary of Warrant HTML 77K Activities (Details) (10-K) 146: R110 Income Taxes (Details Narrative) (10-K) HTML 71K 147: R111 Income Taxes - Schedule of Current and Deferred HTML 89K Income Tax Provision (Benefit) (Details) (10-K) 148: R112 Income Taxes - Schedule of Deferred Tax Assets and HTML 95K Liabilities (Details) (10-K) 149: R113 Income Taxes - Schedule of Reconciliation of HTML 72K Expected Income Taxes (Details) (10-K) 150: R114 Debt (Details Narrative) HTML 159K 151: R115 Long-term Debt (Details Narrative) (10-K) HTML 88K 152: R116 Leases (Details Narrative) HTML 122K 153: R117 Leases (Details Narrative) (10-K) HTML 78K 154: R118 Leases - Schedule of Operating Lease Right-of-use HTML 79K Assets and Liabilities (Details) 155: R119 Leases - Schedule of Operating Lease Right-of-use HTML 74K Assets and Liabilities (Details) (10-K) 156: R120 Leases - Schedule of Maturities of Operating HTML 74K Leases (Details) (10-K) 157: R121 Leases - Schedule of Financing Lease Right-of-use HTML 67K Assets and Liabilities (Details) 158: R122 Leases - Schedule of Financing Lease Right-of-use HTML 66K Assets and Liabilities (Details) (10-K) 159: R123 Leases - Schedule of Maturities of Financing HTML 64K Leases (Details) 160: R124 Leases - Schedule of Maturities of Financing HTML 65K Leases (Details) (10-K) 161: R125 Disposition of Site Equipment to Be Installed and HTML 70K Fixed Assets (Details Narrative) 162: R126 Software Development Costs (Details Narrative) HTML 62K 163: R127 Goodwill (Details Narrative) HTML 60K 164: R128 Goodwill (Details Narrative) (10-K) HTML 60K 165: R129 Goodwill - Schedule of Goodwill (Details) HTML 63K 166: R130 Goodwill - Schedule of Goodwill (Details) (10-K) HTML 64K 167: R131 Accumulated Other Comprehensive Income (Details HTML 57K Narrative) 168: R132 Accumulated Other Comprehensive Income (Details HTML 57K Narrative) (10-K) 169: R133 Retirement Savings Plan (Details Narrative) (10-K) HTML 57K 170: R134 Subsequent Events (Details Narrative) HTML 63K 171: R135 Subsequent Events (Details Narrative) (10-K) HTML 121K 172: R136 Going Conern (Details Narrative) (Brooklyn HTML 68K ImmunoTherapeutics, LLC) 173: R137 Basis of Presentation and Summary of Significant HTML 62K Accounting Policies (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) 174: R138 Merger With NTN Buzztime, Inc (Details Narrative) HTML 68K (Brooklyn ImmunoTherapeutics, LLC) 175: R139 Fair Value of Financial Instruments (Details HTML 61K Narrative) (Brooklyn ImmunoTherapeutics, LLC) 176: R140 Fair Value of Financial Instruments - Schedule of HTML 64K Fair Value of Liabilities (Details) (Brooklyn ImmunoTherapeutics, LLC) 177: R141 Property and Equipment (Details Narrative) HTML 56K (Brooklyn ImmunoTherapeutics, LLC) 178: R142 Property and Equipment - Schedule of Property and HTML 68K Equipment (Details) (Brooklyn ImmunoTherapeutics, LLC) 179: R143 Security Deposits and Other Assets (Details HTML 62K Narrative) (Brooklyn ImmunoTherapeutics, LLC) 180: R144 Accrued Expenses (Details) (Brooklyn HTML 67K ImmunoTherapeutics, LLC) 181: R145 Loans Payable (Details Narrative) (Brooklyn HTML 59K ImmunoTherapeutics, LLC) 182: R146 Commitments and Contingencies (Details Narrative) HTML 99K (Brooklyn ImmunoTherapeutics, LLC) 183: R147 Stock-Based Compensation (Details Narrative) HTML 56K (Brooklyn ImmunoTherapeutics, LLC) 184: R148 Members' Equity (Details Narrative) (Brooklyn HTML 67K ImmunoTherapeutics, LLC) 185: R149 Going Conern (Details Narrative) (Brooklyn HTML 86K ImmunoTherapeutics, LLC) (10-K) 186: R150 Summary of Significant Accounting Policies HTML 72K (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 187: R151 Business Combination (Details Narrative) (Brooklyn HTML 63K ImmunoTherapeutics, LLC) (10-K) 188: R152 Business Combination - Schedule of Purchase Price HTML 83K for Acquisition (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 189: R153 Property and Equipment (Details Narative) HTML 63K (Brooklyn ImmunoTherapeutics, LLC) (10-K) 190: R154 Property and Equipment - Schedule of Property and HTML 68K Equipment (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 191: R155 Goodwill and in Process Research and Development HTML 59K (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 192: R156 Security Deposits and Other Assets (Details HTML 65K Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 193: R157 Accrued Expenses (Details) (Brooklyn HTML 70K ImmunoTherapeutics, LLC) (10K) 194: R158 Investor Deposits (Details Narrative) (Brooklyn HTML 55K ImmunoTherapeutics, LLC) (10-K) 195: R159 Loans Payable and Loans Payable to Related Parties HTML 101K (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 196: R160 Commitments and Contingencies (Details Narrative) HTML 130K (Brooklyn ImmunoTherapeutics, LLC) (10-K) 197: R161 Commitments and Contingencies - Schedule of Future HTML 72K Commitments of Operating Lease (Details) (Brooklyn ImmunoTherapeutics, LLC) 198: R162 Stockholders' Deficiency and Members' Equity HTML 167K (Details Narrative) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 199: R163 Stockholders' Deficiency and Members' Equity - HTML 92K Schedule of Stock Option Activity (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 200: R164 Stockholders' Deficiency and Members' Equity - HTML 70K Schedule of Stock Options Outstanding and Exercisable (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 201: R165 Income Tax (Details Narrative) (Brooklyn HTML 61K ImmunoTherapeutics, LLC) (10-K) 202: R166 Income Tax - Schedule of Income Tax Benefit HTML 84K (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 203: R167 Income Tax - Schedule of Deferred Tax Assets and HTML 61K Liabilities (Details) (Brooklyn ImmunoTherapeutics, LLC) (10-K) 204: R168 Subsequent Events (Details Narrative) (Brooklyn HTML 61K ImmunoTherapeutics, LLC) (10-K) 206: XML IDEA XML File -- Filing Summary XML 371K 205: EXCEL IDEA Workbook of Financial Reports XLSX 284K 31: EX-101.INS XBRL Instance -- ntn-20200930 XML 3.47M 33: EX-101.CAL XBRL Calculations -- ntn-20200930_cal XML 459K 34: EX-101.DEF XBRL Definitions -- ntn-20200930_def XML 2.03M 35: EX-101.LAB XBRL Labels -- ntn-20200930_lab XML 2.11M 36: EX-101.PRE XBRL Presentations -- ntn-20200930_pre XML 2.34M 32: EX-101.SCH XBRL Schema -- ntn-20200930 XSD 461K 207: ZIP XBRL Zipped Folder -- 0001493152-20-022484-xbrl Zip 337K
Exhibit 99.13
Consent to be Named as a Director
In connection with the filing of by NTN Buzztime, Inc. of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act”), I hereby consent, pursuant to Rule 438 under the Act, to be named to the Board of Directors of NTN Buzztime, Inc., and any successor thereto, as described in the Registration Statement and any and all amendments and supplements thereto. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: | November 24, 2020 | |
/s/ Nicholas J. Singer | ||
Nicholas J. Singer |
C:
This ‘S-4/A’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 11/25/20 | CORRESP | ||
11/24/20 | ||||
List all Filings |
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 7/01/22 Eterna Therapeutics Inc. 10-K/A 12/31/21 92:11M Broadridge Fin’l So… Inc 4/15/22 Eterna Therapeutics Inc. 10-K 12/31/21 95:10M Broadridge Fin’l So… Inc 11/23/21 Eterna Therapeutics Inc. S-1/A 2:185K Broadridge Fin’l So… Inc 11/18/21 Eterna Therapeutics Inc. S-1 4:602K Broadridge Fin’l So… Inc 5/27/21 Eterna Therapeutics Inc. S-1 4:660K Broadridge Fin’l So… Inc 4/30/21 Eterna Therapeutics Inc. S-1 8:2.2M Broadridge Fin’l So… Inc 1/20/21 Eterna Therapeutics Inc. S-4/A 1/19/21 182:20M M2 Compliance LLC/FA 12/22/20 Eterna Therapeutics Inc. S-4/A 183:20M M2 Compliance LLC/FA |